Grifols (GIFLF) Non Operating Income (2009 - 2021)
Grifols' (GIFLF) quarterly Non Operating Income came in at $85.6 million in Q4 2021, up 0.82% on a YoY basis from $84.9 million in Q4 2020, and up 0.82% quarter-over-quarter from $84.9 million in Q4 2020.
Analysis
Grifols (GIFLF) Non Operating Income (2009 - 2021) Analysis & Trends
Grifols (GIFLF) has reported Non Operating Income for 10 consecutive years, with $85.6 million the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Non Operating Income rose 0.82% year-over-year to $85.6 million; the trailing twelve-month figure through Dec 2021 stood at $303.7 million (up 1.17% YoY), and the FY2021 full-year result was $85.6 million, up 0.82% from the prior year.
- Non Operating Income climbed to $85.6 million in Q4 2021 per GIFLF's latest filing, from $84.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $85.6 million in Q4 2021 and bottomed at $71.0 million in Q4 2019.
- Historically, Non Operating Income has averaged $80.5 million across 3 years, with a median of $84.9 million in 2020.
- The sharpest annual moves came in 2020 and 2021: Non Operating Income gained 19.72% in 2020, then grew 0.82% in 2021.
- Over 3 years, Non Operating Income stood at $71.0 million in 2019, then increased by 19.72% to $84.9 million in 2020, then climbed by 0.82% to $85.6 million in 2021.
- According to Business Quant data, Non Operating Income over the past three periods registered $85.6 million, $84.9 million, and $71.0 million for Q4 2021, Q4 2020, and Q4 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 85.64 Mn |
| Dec 31, 2020 | 84.94 Mn |
| Dec 31, 2019 | 70.95 Mn |
| Dec 31, 2015 | 62.20 Mn |
| Dec 31, 2014 | 82.14 Mn |
| Dec 31, 2013 | 59.45 Mn |
| Dec 31, 2012 | 3.98 Mn |
| Dec 31, 2011 | 6.68 Mn |
| Dec 31, 2010 | 452,204.83 |
| Dec 31, 2009 | 1.16 Mn |